Trials / Completed
CompletedNCT04318509
Market Research - Acceptability Study for a New PKU Protein Substitute
Market Research - Acceptability Study for a New PKU Glycomacropeptide Based Protein Substitute (Dr Schär- Mevalia Amino Acids) Mevalia PKU GMPower - Vanilla
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Dr. Schär AG / SPA · Industry
- Sex
- All
- Age
- 3 Years – 16 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | GMPOWER | (casein) glycomacropeptide protein substitute for the dietary management of PKU from the age of 3 years |
Timeline
- Start date
- 2019-02-04
- Primary completion
- 2019-05-19
- Completion
- 2019-05-19
- First posted
- 2020-03-24
- Last updated
- 2020-03-24
Locations
2 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04318509. Inclusion in this directory is not an endorsement.